Respiratory infection

4P021

4Living Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase II

Pharmaceutical partner:
Sanofi

Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute and chronic pulmonary complications due to viral infection.
A first international proof of concept phase 2b trial is launched to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.
4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.
Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

Milestone:
Phase II trial on Covid-19 patients.

Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).

Osteoarthritis

4P004

4Moving Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase I

Pharmaceutical partner:
Partnering opportunity

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.

4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.

Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
Phase I trial on OA patients

Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)

Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Addiction

4P003

Addiction

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase I

Pharmaceutical partner:
Partnering opportunity

Summary:
4P003 is a first-in-class proprietary fixed dose combination developed with the objective to prevent abuse and misuse of prescribed stimulants and particularly methylphenidate, used for the treatment of attention deficit hyperactivity disorder (ADHD). 

Milestone:
pre-IND

Market:
ADHD market > $10 billion

Macular degeneration

4P020

Stargardt disease (orphan)

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Preclinical

Summary:
4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for Stargardt disease in collaboration with Institut de la Vision and SATT Lutech.

Milestone: 

Incorporation in an asset-centric company

Epidemiology:

Stargardt disease is a rare disease with an estimated prevalence of 1/8,000 – 1/10,000 individuals. (Orphanet)

Macular degeneration

4P020

Dry Age-related Macular Degeneration

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Preclinical

Summary:
4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for dry AMD in collaboration with Institut de la Vision and SATT Lutech.

Milestone:
Incorporation in an asset-centric company

Epidemiology:
With population ageing worldwide, it is estimated that the number of people affected by dry AMD will increase to 230 – 259 Millions in 2040 (Deng et al., 2021).

ALS

4P019

Neurodegenerative diseases

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Drug discovery achieved
Scleroderma

4P022

Systemic sclerosis (orphan)

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Drug discovery

Summary:
With our partner, Oncocross, a Korea based AI biotech, we are developing an AI platform-based treatment for systemic sclerosis.

Epidemiology:
Systemic sclerosis is a rare disease with an estimated prevalence of 1/6,500 individuals. (Orphanet)

 

Rare autoimmune chronic disease

4P025

Liver disease (orphan disease)

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Drug discovery

Pharmaceutical partner:
Not open to partnerships

Summary :
In partnerships with Delta 4, an AI biotech company based in Vienna (Austria), we join forces to discover and develop a drug candidate from Delta 4’s platform, for the treatment of a rare autoimmune chronic liver disease.